Recent 8-K filings for WVE

• May 18, 2026, 4:51 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Wave Life Sciences WVE-006 phase 1b/2a data shows MZ-like phenotype with monthly dosing, FDA feedback expected mid-2026

  WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.

• April 28, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026

  Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).

• March 26, 2026, 7:59 PM ET other material materiality 0.90 positive item 7.01item 8.01item 9.01

  Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial

  Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.

• February 26, 2026, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026

  Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.

• February 2, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026

  Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.

• January 12, 2026, 6:59 PM ET other material materiality 0.60 positive item 2.02item 7.01item 9.01

  Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones

  Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.

• December 11, 2025, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 7.01item 8.01item 9.01

  Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028

  Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.

• December 8, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive Phase 1 INLIGHT data: WVE-007 reduces visceral fat 9.4%, preserves lean mass

  Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.

• November 10, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction

  WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.

• October 30, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive WVE-007 target engagement: up to 85% Activin E reduction; WVE-008 candidate selected

  WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.

• October 29, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive target engagement data for WVE-007 in obesity; Activin E reductions up to 85%

  WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).

• September 3, 2025, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study

  200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels

• July 30, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track

  Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD

  Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.

• March 26, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave reports positive Phase 2 FORWARD-53 data for WVE-N531 in DMD; plans NDA in 2026

  TTR improved 3.8 seconds vs natural history (p<0.05); fibrosis reduced 28.6% (p<0.01); CK declined 50%.

• March 4, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025

  Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved

  Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).

• October 16, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave achieves first-ever therapeutic RNA editing in humans in RestorAATion-2 trial of WVE-006

  Single 200 mg dose in first two Pi*ZZ patients produced mean total AAT ~11 µM at day 15, with edited M-AAT >60% of total.

• October 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01

  Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program

  Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.

• September 26, 2024, 7:59 PM ET other material materiality 0.85 neutral item 1.01item 7.01item 8.01item 9.01

  Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants

  Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.

• September 24, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports positive interim Phase 2 data for WVE-N531: adjusted dystrophin 9.0% in DMD exon 53

  Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Wave Life Sciences Q2 net loss $32.9M; positive HD data with up to 46% mHTT reduction; cash $154M into Q4 2025

  Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.

• June 25, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated

  SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track

  Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event other_material

19 positive 2 negative 14 neutral

source · WVE on sec.gov